Filtered By:
Therapy: Immunotherapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 29516 results found since Jan 2013.
Integrative landscape analysis of prognostic model biomarkers and immunogenomics of disulfidptosis-related genes in breast cancer based on LASSO and WGCNA analyses
CONCLUSION: The risk score model was effective for predicting both prognosis and sensitivity to therapeutic drugs, suggesting its possible usefulness for the management of patients with breast cancer.PMID:37736788 | DOI:10.1007/s00432-023-05372-z
Source: Clinical Breast Cancer - September 22, 2023 Category: Cancer & Oncology Authors: Shuyan Liu Yiwen Zheng Shujin Li Yaoqiang Du Xiaozhen Liu Hongchao Tang Xuli Meng Qinghui Zheng Source Type: research
Non-coding RNAs in cancer immunotherapy: Predictive biomarkers and targets
CONCLUSION: This review summarises important predictive ncRNA biomarkers that were reported in cancer patients treated with different immunotherapeutic modalities, including monoclonal antibodies, small molecule inhibitors, cancer vaccines and CAR-T cells. In addition, a concise discussion on forthcoming perspectives is provided, outlining technical approaches for the optimal utilisation of immunomodulatory ncRNA biomarkers as predictive tools and therapeutic targets.PMID:37735815 | DOI:10.1002/ctm2.1425
Source: Clinical Lung Cancer - September 22, 2023 Category: Cancer & Oncology Authors: Murad Alahdal Eyad Elkord Source Type: research
Integrative landscape analysis of prognostic model biomarkers and immunogenomics of disulfidptosis-related genes in breast cancer based on LASSO and WGCNA analyses
CONCLUSION: The risk score model was effective for predicting both prognosis and sensitivity to therapeutic drugs, suggesting its possible usefulness for the management of patients with breast cancer.PMID:37736788 | DOI:10.1007/s00432-023-05372-z
Source: Clinical Genitourinary Cancer - September 22, 2023 Category: Cancer & Oncology Authors: Shuyan Liu Yiwen Zheng Shujin Li Yaoqiang Du Xiaozhen Liu Hongchao Tang Xuli Meng Qinghui Zheng Source Type: research
Non-coding RNAs in cancer immunotherapy: Predictive biomarkers and targets
CONCLUSION: This review summarises important predictive ncRNA biomarkers that were reported in cancer patients treated with different immunotherapeutic modalities, including monoclonal antibodies, small molecule inhibitors, cancer vaccines and CAR-T cells. In addition, a concise discussion on forthcoming perspectives is provided, outlining technical approaches for the optimal utilisation of immunomodulatory ncRNA biomarkers as predictive tools and therapeutic targets.PMID:37735815 | DOI:10.1002/ctm2.1425
Source: Clinical Colorectal Cancer - September 22, 2023 Category: Cancer & Oncology Authors: Murad Alahdal Eyad Elkord Source Type: research
Cytotoxicity of WT1-reactive T cells against Wilms tumor: An implication for antigen-specific adoptive immunotherapy
CONCLUSION: WT1-reactive T cells can be effectively enriched from the PBMCs of patients with Wilms tumor. Ex vivo generated WT1-reactive T cells might be considered an adoptive immunotherapeutic option for WT1+ Wilms tumors.PMID:37736339 | PMC:PMC10509739 | DOI:10.34172/bi.2023.27576
Source: Cancer Control - September 22, 2023 Category: Cancer & Oncology Authors: Seyed Mostafa Monzavi Amir Ali Hamidieh Mohammad Vasei Jafar Ai Naser Ahmadbeigi Hamid Arshadi Samad Muhammadnejad Abdol-Mohammad Kajbafzadeh Source Type: research
Single-cell and bulk sequencing analyses reveal the immune suppressive role of PTPN6 in glioblastoma
Aging (Albany NY). 2023 Sep 21;15. doi: 10.18632/aging.205052. Online ahead of print.ABSTRACTGlioblastoma (GBM) is a highly malignant brain cancer with a poor prognosis despite standard treatments. This investigation aimed to explore the feasibility of PTPN6 to combat GBM with immunotherapy. Our study employed a comprehensive analysis of publicly available datasets and functional experiments to assess PTPN6 gene expression, prognostic value, and related immune characteristics in glioma. We evaluated the influence of PTPN6 expression on CD8+ T cell exhaustion, immune suppression, and tumor growth in human GBM samples and mo...
Source: Aging - September 22, 2023 Category: Biomedical Science Authors: Xiaonan Zhang Jie Chen Ming Zhang Saisai Liu Tao Wang Tianyu Wu Baiqing Li Shidi Zhao Hongtao Wang Li Li Chun Wang Li Huang Source Type: research
Construction of an anoikis ‒related prognostic signature to predict immunotherapeutic response and prognosis in hepatocellular carcinoma
CONCLUSION: A successful anoikis-related prognostic signature and corresponding clinical nomogram were established, which might facilitate better predictions of prognosis and therapeutic responses for HCC patients.PMID:37736789 | DOI:10.1007/s00432-023-05428-0
Source: Cell Research - September 22, 2023 Category: Cytology Authors: Chen Xiong Guoqiang Pan Hanchao Wang Guangxiao Meng Lunjie Yan Ruizhe Li Yuchuan Yan Yafei Yang Xiao Zhang Chuncheng Yang Zhaoru Dong Tao Li Source Type: research
Integrative landscape analysis of prognostic model biomarkers and immunogenomics of disulfidptosis-related genes in breast cancer based on LASSO and WGCNA analyses
CONCLUSION: The risk score model was effective for predicting both prognosis and sensitivity to therapeutic drugs, suggesting its possible usefulness for the management of patients with breast cancer.PMID:37736788 | DOI:10.1007/s00432-023-05372-z
Source: Cell Research - September 22, 2023 Category: Cytology Authors: Shuyan Liu Yiwen Zheng Shujin Li Yaoqiang Du Xiaozhen Liu Hongchao Tang Xuli Meng Qinghui Zheng Source Type: research
Personalized Immunotherapy of Patients: Defining by Single-cell RNA-seq with Artificial Intelligence
Med Res Arch. 2023 Aug;11(8):10.18103/mra.v11i8.4293. doi: 10.18103/mra.v11i8.4293. Epub 2023 Aug 30.ABSTRACTImmunotherapy, including immune cell therapy and targeted therapy, is gradually developed through the ongoing discovery of molecular compounds or immune cells. Choosing the best one or the best combination of target compounds and immune-cell therapy is a challenge for clinical scientists and clinicians. We have found variable efficacy individually after tumor-infiltrating lymphocyte (TIL) therapy, and now TILs have been discovered in a group of heterogeneous immune cells. To select the best immunotherapy for each pa...
Source: Cell Research - September 22, 2023 Category: Cytology Authors: Biaoru Li Source Type: research
CYFIP2 serves as a prognostic biomarker and correlates with tumor immune microenvironment in human cancers
CONCLUSION: Our results suggested that CYFIP2 may serve as a prognostic cancer biomarker for determining prognosis and might be a promising therapeutic strategy for tumor immunotherapy.PMID:37735711 | DOI:10.1186/s40001-023-01366-2
Source: Cell Research - September 22, 2023 Category: Cytology Authors: Qiliang Peng Bixin Ren Kedao Xin Weihui Liu Md Shahin Alam Yinyin Yang Xuhao Gu Yaqun Zhu Ye Tian Source Type: research
Boiling histotripsy induces dendritic cell activation and acquisition of antigen in tumor draining lymph nodes
bioRxiv. 2023 Sep 6:2023.09.02.552844. doi: 10.1101/2023.09.02.552844. Preprint.ABSTRACTBoiling histotripsy (BH), a mechanical focused ultrasound ablation strategy, can elicit intriguing signatures of anti-tumor immunity. However, the influence of BH on dendritic cell function is unknown, compromising our ability to optimally combine BH with immunotherapies to control metastatic disease. Here, by applying BH to B16F10 melanoma expressing a ZsGreen antigen in a monotherapy protocol that elicits abscopal tumor control, we observed a marked increase in antigen acquisition by multiple phagocytic immune cells, including convent...
Source: Cancer Control - September 21, 2023 Category: Cancer & Oncology Authors: Eric A Thim Lydia E Petricca F átima Rivera-Escalera Alexander S Mathew Michael R Elliott Timothy N J Bullock Richard J Price Source Type: research
Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review
CONCLUSIONS: Cumulatively, these results support the combination of ramucirumab plus docetaxel as an effective and safe subsequent therapy for the treatment of patients with metastatic NSCLC with disease progression irrespective of previous ICI treatment.PMID:37731641 | PMC:PMC10507469 | DOI:10.3389/fonc.2023.1247879
Source: Cancer Control - September 21, 2023 Category: Cancer & Oncology Authors: Edward B Garon Carla Visseren-Grul Maria Teresa Rizzo Tarun Puri Suresh Chenji Martin Reck Source Type: research
Topical Calcipotriol Plus Imiquimod Immunotherapy for Nonkeratinocyte Skin Cancers
In this study, we demonstrate that topical TSLP cytokine inducers-calcipotriol and retinoic acid-synergize with IMQ to activate CD4+ T-cell immunity against nonkeratinocyte cutaneous malignancies. Topical calcipotriol plus IMQ treatment reduced breast tumor growth compared with calcipotriol or IMQ alone (P < 0.0001). Calcipotriol plus IMQ-mediated tumor suppression was associated with significant infiltration of CD4+ effector T cells in the tumor microenvironment. Notably, topical calcipotriol plus IMQ immunotherapy enabled immune checkpoint blockade therapy to effectively control immunologically cold breast tumors, whi...
Source: Cancer Control - September 21, 2023 Category: Cancer & Oncology Authors: Marjan Azin Kenneth H Ngo Jennet Hojanazarova Shadmehr Demehri Source Type: research
Albendazole induces an anti-tumor effect and potentiates PD-L1 blockade immunotherapy
CONCLUSION: ABZ inhibits melanoma growth and metastasis. Moreover, ABZ synergized with PD-L1 blockade mediates tumor regression.PMID:37730912 | DOI:10.1007/s00432-023-05415-5
Source: Cancer Control - September 21, 2023 Category: Cancer & Oncology Authors: Weinan Zhang Zhiqiang He Fucheng Liang Jie Gong Liuchang Tan Juan Yang Siji Song Luoyingzi Xie Yuangang Lu Source Type: research
